Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period

NCT00299676 is registered in ClinicalTrials.gov with Janssen-Cilag Pty Ltd as lead sponsor.

NCT NCT00299676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00299676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period
Lead sponsor
Janssen-Cilag Pty Ltd
Phase
Observational
Overall status
Completed
Start date
May 31, 2005
Completion date
March 31, 2008
Enrollment
61 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, dementia, galantamine